Acute myelogenous leukemia
Authors:
- James N. ButeraJBJames N. Butera
- 1 June 2009
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 37 (6) , 649-658
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Multicentre phase III trial on fludarabine, cytarabine (Ara‐C), and idarubicin versus idarubicin, Ara‐C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patientsBritish Journal of Haematology, 2005
- Biology and management of relapsed acute myeloid leukaemiaBritish Journal of Haematology, 2005
- The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitroEuropean Journal of Haematology, 2004
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003
- Comparison of allogeneic stem cell transplantation, high‐dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemiaCancer, 2003